94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Nguyen Van Hiep1,2,3
Wei-Lun Sun4,5,6
Po-Hao Feng4,5,6Cheng-Wei Lin1,6,7Kuan-Yuan Chen4,5,6,8Ching-Shan Luo1,4,6Le Ngoc Dung3Hoang Van Quyet3
Sheng-Ming Wu4,5,6*
Kang-Yun Lee1,4,5,6,8*- 1International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- 2Oncology Center, Bai Chay Hospital, Quang Ninh, Ha Long, Vietnam
- 3Department of Thoracic and Neurological Surgery, Bai Chay Hospital, Quang Ninh, Ha Long, Vietnam
- 4Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
- 5Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- 6TMU Research Center for Thoracic Medicine, Taipei Medical University, Taipei, Taiwan
- 7Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
by Van Hiep N, Sun W-L, Feng P-H, Lin C-W, Chen K-Y, Luo C-S, Dung LN, Van Quyet H, Wu S-M and Lee K-Y (2022) 12:963896. doi: 10.3389/fonc.2022.963896
In the published article, there was an error in affiliation 1. Instead of “IInternational Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan”, it should be “International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan”.
In the published article, there was an error in the Ethics statement. The IRB number was incorrectly displayed as “IRB no. N20210313”. The correct IRB number is “IRB no. N202103013”. The correct Ethics statement appears below.
Ethics statement
The study protocol was approved by the Joint Institutional Review Board of Taipei Medical University (IRB no. N202103013). The patients/participants provided their written informed consent to participate in this study.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: heparin-binding EGF-like growth factor (HBEGF), bioinformatics, biomarker, immune infiltration, macrophage chemotaxis, non-small cell lung cancer
Citation: Van Hiep N, Sun W-L, Feng P-H, Lin C-W, Chen K-Y, Luo C-S, Dung LN, Van Quyet H, Wu S-M and Lee K-Y (2022) Corrigendum: Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma. Front. Oncol. 12:1106553. doi: 10.3389/fonc.2022.1106553
Received: 23 November 2022; Accepted: 29 November 2022;
Published: 13 December 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Van Hiep, Sun, Feng, Lin, Chen, Luo, Dung, Van Quyet, Wu and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kang-Yun Lee, bGVla2FuZ3l1bkB0bXUuZWR1LnR3; Sheng-Ming Wu, Y2hpdG9zYW5AdG11LmVkdS50dw==